Jove
Visualize
Contact Us

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

42
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Dementia01:30

Dementia

693
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
693
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems.

The Medical journal of Australia·2023
Same author

Research gaps and opportunities in precision nutrition: an NIH workshop report.

The American journal of clinical nutrition·2022
Same author

Decompensation of cardiorespiratory function and emergence of anemia during pregnancy in a case of mitochondrial myopathy, lactic acidosis, and sideroblastic anemia 2 with compound heterozygous YARS2 pathogenic variants.

American journal of medical genetics. Part A·2022
Same author

Approach to Common Visual Complaints Presenting to the Outpatient Neurologist.

Seminars in neurology·2021
Same author

Feasibility of a wearable biosensor device to characterize exercise and sleep in neurology residents.

Expert review of medical devices·2021
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 6, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

9.8K

Alzheimer's disease.

Carly Oboudiyat1, Hilary Glazer, Alon Seifan

  • 1Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida.

Seminars in Neurology
|November 16, 2013
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) is a leading cause of dementia. Early diagnosis and prevention strategies targeting preclinical AD offer the best potential for intervention and disease modification.

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K

Related Experiment Videos

Last Updated: May 6, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

9.8K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.1K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

13.9K

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is the most common cause of dementia, leading to significant morbidity, mortality, and healthcare costs.
  • Pathological changes like amyloid plaques, tau tangles, and metabolic dysfunction can begin decades before symptom onset.
  • Understanding modifiable and nonmodifiable risk factors is crucial for early intervention.

Purpose of the Study:

  • To review the latest diagnostic criteria for Alzheimer's disease, including preclinical AD.
  • To discuss current pharmacologic and nonpharmacologic therapeutic strategies for AD.
  • To explore the role of genetic factors and personalized nutrition in AD management.

Main Methods:

  • Literature review of recent diagnostic criteria and treatment guidelines for Alzheimer's disease.
  • Analysis of evidence for pharmacologic and nonpharmacologic interventions.
  • Examination of genetic factors (APOE ε4) and nutritional approaches in AD.

Main Results:

  • The earliest diagnostic stage, preclinical AD, presents a key window for research and intervention.
  • Both FDA-approved drugs and evidence-based lifestyle interventions can be used for AD therapeutics and prevention.
  • Genetic factors, such as APOE ε4, and personalized nutrition (nutrigenomics) are increasingly important in managing AD.

Conclusions:

  • Early detection and intervention in preclinical Alzheimer's disease are critical.
  • A combination of pharmacologic, nonpharmacologic, and personalized strategies, including genetic and nutritional considerations, is essential for managing AD.
  • Further research into pharmacogenomics and nutrigenomics holds promise for tailored AD treatments.